Jiang, Nan
Dalian Medical University · Second Affiliated Hospital of Dalian Medical University
4 papers on CoChatORCID 0000-0003-2416-1653
Most cited papers
- Verified
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 595
- Verified
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters
Cancer-related Molecular PathwaysHeat shock proteins research
Cited by 395
- Verified
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T. M., Zhao, J. J., Liu, P., & Cheng, H. (2016) · Oncotarget
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment
Cited by 88
- Verified
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 60
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free